Robertson F M, Offner P J, Ciceri D P, Becker W K, Pruitt B A
Department of Surgery, Brooke Army Medical Center, Fort Sam Houston, Tex.
Arch Surg. 1994 Feb;129(2):149-55; discussion 155-6. doi: 10.1001/archsurg.1994.01420260045005.
To investigate the physiologic effects of nitric oxide synthase inhibition with N-nitro-L-arginine methyl ester in an acute resuscitated model of porcine septic shock.
Randomized control trial.
Animal research facility.
Domestic Yorkshire swine.
Twenty-four animals were randomly divided into one of four treatment groups as follows: normal saline resuscitation (NSR) (control group); NSR plus 200 micrograms/kg of lipopolysaccharide (LPS) at 1 hour after baseline (LPS group); NSR, LPS, and a continuous infusion of 50 micrograms/kg per minute of N-nitro-L-arginine methyl ester (NAME) at 1 hour after baseline (LPS/NAME group); and NSR and NAME (NAME group). All animals received NSR at 1 mL/kg per minute starting at baseline.
Mean arterial pressure (MAP), systemic vascular resistance index (SVRI), mean pulmonary arterial pressure (MPAP), and pulmonary vascular resistance index (PVRI) were measured at baseline and hourly for 4 hours. Values at baseline and 3 hours are given below as mean (+/- SE).
All variables remained unchanged in the control group. The administration of LPS produced a systemic hyperdynamic response characterized by a decrease in MAP and SVRI from 66.0 +/- 3.9 to 55.0 +/- 2.8 mm Hg (P < .05) and from 422.0 +/- 22.0 to 272.0 +/- 29.0 mm Hg.min.kg/L (P < .05), respectively. The administration of LPS produced an increase in MPAP and PVRI from 16.3 +/- 0.8 to 30.0 +/- 1.3 mm Hg (P < .05) and from 37.0 +/- 5.3 to 119.0 +/- 13.0 mm Hg.min.kg/L (P < .05), respectively. In the LPS/NAME group, NAME infusion normalized MAP and increased SVRI from 506.0 +/- 40.0 to 642.0 +/- 72.0 mm Hg.min.kg/L (P < .05). Infusion of NAME potentiated LPS-induced pulmonary hypertension, increasing MPAP and PVRI from 16.8 +/- 0.6 to 36.0 +/- 2.8 mm Hg (P < .05) and from 59.0 +/- 3.5 to 319.0 +/- 64.0 mm Hg.min.kg/L (P < .05), respectively. Infusion of NAME alone increased MAP from 74.0 +/- 1.3 to 100.0 +/- 4.1 mm Hg (P < .05) and had no significant effect on MPAP and PVRI.
The potentiation of LPS-induced pulmonary hypertension following NAME infusion suggests that inhibition of nitric oxide synthase may have a limited role in the treatment of septic shock.
在猪急性复苏性脓毒性休克模型中,研究用N-硝基-L-精氨酸甲酯抑制一氧化氮合酶的生理效应。
随机对照试验。
动物研究设施。
家约克郡猪。
24只动物被随机分为以下四个治疗组之一:生理盐水复苏组(NSR)(对照组);基线后1小时给予NSR加200微克/千克脂多糖(LPS)(LPS组);基线后1小时给予NSR、LPS并持续输注50微克/千克每分钟的N-硝基-L-精氨酸甲酯(NAME)(LPS/NAME组);以及NSR和NAME组(NAME组)。所有动物从基线开始以每分钟1毫升/千克的速度接受NSR。
在基线时和之后4小时每小时测量平均动脉压(MAP)、全身血管阻力指数(SVRI)、平均肺动脉压(MPAP)和肺血管阻力指数(PVRI)。基线和3小时时的值如下以平均值(±标准误)表示。
对照组所有变量均保持不变。给予LPS产生全身高动力反应,其特征为MAP和SVRI分别从66.0±3.9降至55.0±2.8毫米汞柱(P<.05)和从422.0±22.0降至272.0±29.0毫米汞柱·分钟·千克/升(P<.05)。给予LPS使MPAP和PVRI分别从16.3±0.8升至30.0±1.3毫米汞柱(P<.05)和从37.0±5.3升至119.0±13.0毫米汞柱·分钟·千克/升(P<.05)。在LPS/NAME组中,输注NAME使MAP恢复正常,并使SVRI从506.0±40.0升至642.0±72.0毫米汞柱·分钟·千克/升(P<.05)。输注NAME增强了LPS诱导的肺动脉高压,使MPAP和PVRI分别从16.8±0.6升至36.0±2.8毫米汞柱(P<.05)和从59.0±3.5升至319.0±64.0毫米汞柱·分钟·千克/升(P<.05)。单独输注NAME使MAP从74.0±1.3升至100.0±4.1毫米汞柱(P<.05),对MPAP和PVRI无显著影响。
输注NAME后LPS诱导的肺动脉高压增强表明,抑制一氧化氮合酶在脓毒性休克治疗中可能作用有限。